Trevena (NASDAQ:TRVN) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Trading Down 14.7 %

Shares of NASDAQ:TRVN opened at $4.01 on Friday. Trevena has a 12-month low of $3.35 and a 12-month high of $25.75. The business’s fifty day simple moving average is $2.72 and its 200-day simple moving average is $1.21. The company has a market capitalization of $73.55 million, a PE ratio of -1.50 and a beta of 1.03.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.36. The company had revenue of $0.33 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC purchased a new stake in shares of Trevena, Inc. (NASDAQ:TRVN) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena as of its most recent filing with the SEC. Institutional investors own 13.56% of the company’s stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.